

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/62, 15/63, C07K 14/00, G01N 33/543		(11) International Publication Number: WO 95/05469
A1		(43) International Publication Date: 23 February 1995 (23.02.95)
(21) International Application Number: PCT/US94/09298		(81) Designated States: CA, JP, KR, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(22) International Filing Date: 15 August 1994 (15.08.94)		
(30) Priority Data: 08/106,815 16 August 1993 (16.08.93) US		
(71)(72) Applicant and Inventor: LEE, Jong, Y. [US/US]; 514 Huron Boulevard, S.E. #A-11, Minneapolis, MN 55414 (US).		
(74) Agents: ELLINGER, Mark, S. et al.; Patterson & Keough, P.A., 1200 Rand Tower, 527 Marquette Avenue South, Minneapolis, MN 55402 (US).		
Published With international search report.		

(54) Title: HUMAN ERYTHROPOIETIN RECEPTOR FRAGMENT AND ANTIBODIES THERETO

(57) Abstract

A *E. coli* recombinant plasmid expressing a fusion protein having the human erythropoietin receptor extracellular domain is disclosed. A purified fusion protein produced from such a vector is also disclosed, the fusion protein having a cleavage site suitable for separating the erythropoietin receptor extracellular domain from the remainder of the fusion protein. Antibodies having specific binding affinity for a purified extracellular domain polypeptide are also disclosed. The purified human erythropoietin receptor fragment polypeptide binds erythropoietin. The articles, compositions and methods of the invention are useful for studying ligand binding to erythropoietin receptor and for quantitating the amounts of erythropoietin receptor, as well as for understanding receptor structure and signal transduction.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

5

10

HUMAN ERYTHROPOIETIN RECEPTOR FRAGMENT AND ANTIBODIES THERETO

15

Field of the Invention

This invention relates to purified human erythropoietin receptor extracellular domain polypeptide. More particularly, this invention relates to human erythropoietin receptor extracellular domain polypeptide that retains affinity for erythropoietin, to DNA sequences suitable for use in producing such a polypeptide, and to antibodies recognizing such a polypeptide.

Background of the Invention

Erythropoietin (Epo) is a glycoprotein hormone of molecular weight 34 kilodaltons (kDa) that is produced in the mammalian kidney and liver. Epo is a key component in erythropoiesis, inducing the proliferation and differentiation of red cell progenitors. Epo activity also is associated with the activation of a number of erythroid-specific genes, including globin and carbonic anhydrase. Bondurant et al., Mol. Cell Biol. 5:675-683 (1985); Koury et al., J. Cell. Physiol. 126:259-265 (1986). The erythropoietin receptor (EpoR) is a member of the hematopoietic/cytokine/growth factor receptor family, which includes several other growth factor receptors, such as the interleukin (IL)-3, -

4 and -6 receptors, the granulocyte macrophage colony-stimulating factor (GM-CSF) receptor as well as the prolactin and growth hormone receptors. Bazan, Proc. Natl. Acad. Sci USA 87:6934-6938 (1990). Members of the cytokine receptor family contain four conserved residues and a tryptophan-serine-X-
5 tryptophan-serine motif positioned just outside the transmembrane region. The conserved sequences are thought to be involved in protein-protein interactions. Chiba et al., Biochim. Biophys. Res. Comm. 184:485-490 (1992).

EpoR cDNA has been isolated recently from mouse liver, Tojo et al., Biochem. Biophys. Res. Comm. 148: 443-48 (1987) and from human fetal
10 liver. Jones et al., Blood 76:31-35 (1990); Winkelmann et al., Blood 76:24-30 (1990). The human cDNA encodes a polypeptide chain of MW ~55 kDa and having about 508 amino acids. Genomic clones of human EpoR have been isolated and sequenced. Penny and Forget, Genomics 11:974-80 (1991);
15 Noguchi et al., Blood 78:2548-2556 (1991). Analysis of the coding sequence predicts about 24 amino acid residues in a signal peptide, about 226 amino acids in an extracellular domain, about 23 amino acids in a membrane-spanning domain, and about 235 amino acids in a cytoplasmic domain. D'Andrea and Zon, J. Clin. Invest. 86:681-687 (1990); Jones et al., Blood 76:31-35, (1990); Penny and Forget, Genomics 11: 974-80 (1991). The mature human
20 EpoR protein has about 484 amino acids. All human erythroid progenitor cells have been shown to contain Epo receptors. Binding of Epo appears to decline as erythroid progenitor cells mature, until Epo receptors are not detectable on reticulocytes. Sawada et al., J. Clin. Invest. 80:357-366 (1987). Sawada et al., J. Cell. Physiol. 137:337 (1988). Epo maintains the cellular
25 viability of the erythroid progenitor cells and allows them to proceed with mitosis and differentiation. Two major erythroid progenitors responsive to Epo are the Burst-forming units-erythroid (BFU-E) and the Colony-forming units-erythroid (CFU-E). The Epo receptor number correlates very well with the response to Epo in normal BFU-E and CFU-E. Epo receptor numbers
30 appear to decline after reaching the peak receptor number at the CFU-E stage in human and murine cells. Sawada et al., J. Clin. Invest. 80:357-366 (1987); Landschulz et al., Blood 73:1476-1486 (1989). The recovery of Epo receptors

after removal of Epo appears to be dependent on protein synthesis, which suggests downregulation of Epo receptor by degradation, and the subsequent upregulation of receptors by the new synthesis of receptors when Epo is removed. Sawyer and Hankins, Blood 72:132 (1988). Studies of Epo receptors on megakaryocytes and erythroid progenitors suggest that there is a link between the regulation of erythropoiesis and thrombopoiesis, in that stimulation of cell division by both cell types is controlled by Epo receptor numbers. Berridge et al., Blood 72:970-977 (1988). Although the Epo receptor has been cloned, the precise mechanisms involved in binding of Epo to Epo receptors and the relationship to subsequent erythropoietic processes are not known.

Characterization of the Epo receptor (EpoR) has been difficult due to the extremely small quantities of EpoR that can be obtained from natural sources. Thus, the mechanism of Epo interaction with its receptor, which stimulates erythropoiesis, is still unknown. D'Andrea and Zon, J. Clin. Invest. 86:681-687 (1990). Recently this mechanism has been of great interest in understanding the role of growth factors and their receptors in leukemogenesis; altered hematopoietic growth factors and their receptors may contribute to tumorigenesis and leukemogenesis. Dunbar et al., Science 245:1493-1496 (1989); Li et al., J. Virol. 57:534-538 (1986).

Several studies of the correlation between the Epo responsiveness of a particular cell type and the affinity of the cell type for Epo have reported discordant results. These studies have used recombinant Epo or EpoR possessing some non-native amino acid sequence from the corresponding plasmid vectors. Berridge et al., Blood 72:970-977 (1988); Harris et al., J. Biol. Chem. 267: 15205-09 (1992). It is possible that tertiary structural changes and/or other features of these recombinant Epo or EpoR molecules have changed the characteristics of the native protein. Thus, it would be a significant advance to obtain substantially pure fragments of the Epo receptor, free of extraneous (e.g, vector) amino acid sequence. Although it could not be predicted whether or not such fragments would retain functional activity,

nevertheless a purified extracellular domain fragment would be particularly useful since Epo binds to the extracellular domain of the Epo receptor.

Summary of the Invention

5 An expression vector is disclosed, comprising a first nucleotide sequence capable of expressing a polypeptide that has a thrombin proteolytic cleavage site near the carboxyl terminus and a second nucleotide sequence consisting essentially of nucleotides 73 to 750 (as enumerated in SEQ ID NO: 4) of a full length human erythropoietin receptor cDNA coding sequence.
10 The Epo receptor cDNA coding sequence fragment is positioned 3' to (downstream of) the proteolytic cleavage site and is in the same translational reading frame as the proteolytic cleavage site. The Epo receptor cDNA coding sequence fragment is oriented to be translationally contiguous with the first polynucleotide sequence.

15 A purified fusion protein is disclosed, comprising a first segment consisting essentially of a polypeptide produced by an expression vector and having a thrombin proteolytic cleavage site, and a second segment consisting essentially of about amino acid 25 to about amino acid 250 (as enumerated in SEQ ID NO: 4) of the full length human erythropoietin receptor protein. The
20 second segment is covalently coupled to the carboxyl end of the first segment. A purified protein, consisting essentially of about amino acid 25 to about amino acid 250 of the full length human erythropoietin receptor protein sequence, may be produced by thrombin cleavage of the fusion protein.

 An antibody having affinity for a purified human erythropoietin
25 receptor polypeptide extracellular domain is disclosed. The antibody has affinity for a polypeptide comprising about amino acid 25 to about amino acid 250 of the full length human erythropoietin receptor protein sequence.

 An immunoassay composition comprising a solid phase reagent and the antibody operably coupled to the solid phase reagent, is disclosed.
30 Also disclosed is an immunoassay composition comprising a solid phase reagent and the purified protein operably coupled to the solid phase reagent.

Methods for obtaining a substantially pure human erythropoietin receptor polypeptide consisting essentially of about amino acid 25 to about amino acid 250 of the full length human erythropoietin receptor protein are disclosed. The substantially pure human erythropoietin receptor polypeptide retains the ability to bind specifically to erythropoietin. The methods include treating the fusion protein with thrombin under conditions allowing cleavage of the polypeptide from the fusion protein, to form a digest mixture; adding the digest mixture to a solid phase reagent having erythropoietin coupled thereto, under conditions allowing binding of the polypeptide with the solid phase reagent, to form a polypeptide-solid phase composition; washing the polypeptide-solid phase composition to remove unbound material; and eluting the substantially pure human erythropoietin receptor polypeptide from the polypeptide-solid phase composition.

15

Brief Description of the Figures

Figure 1 is a diagrammatic representation of pJYL26, a plasmid having about 678 bp of the 5' coding sequence of human erythropoietin receptor cDNA inserted into the expression vector pGEX-2T. Figure 1 also depicts the recombinant fusion protein, EpoRex-th, that is expressed from pJYL26.

Figure 2a shows the absorbance at 280 nanometers (A_{280}) of fractions collected from purification of an *E. coli* cell extract, expressing EpoRex-th, on a glutathione affinity column. Figure 2b shows the A_{280} of fractions containing Epo-bp collected as a result of erythropoietin affinity chromatography of thrombin treated EpoRex-th.

Figure 3 is a photograph of a Coomassie blue stained polyacrylamide gel, showing the cleavage of EpoRex-th by thrombin.

Figure 4 is a Western blot, showing binding of sheep anti-Epo-bp antibody to Epo-bp.

30

Figure 5 shows the binding of various concentrations of human ^{125}I -Epo to Epo-bp, in the presence and absence of unlabeled Epo.

Figure 6 is a photograph of a Coomassie blue stained polyacrylamide gel, showing the polypeptide bands observed after trypsin digestion of Epo-bp.

5

Detailed Description of the Invention

Despite the availability of recombinant human Epo and full-length human Epo receptor cDNA clones, little is known about the interaction of Epo and Epo receptor, or the signal transducing mechanisms involved in proliferation and differentiation of erythroid progenitor cells.

10

Plasmid expression vectors permit expression of a protein from cloned coding sequences that have been inserted into the vector. Expression vectors generally have a selectable marker and a replication origin for selection and maintenance of the vector in a host cell, as well as inducible regulatory elements for inducing high level expression of a polypeptide suitable for fusing to an inserted gene. It is preferred that convenient restriction sites be engineered into the vector downstream from a proteolytic cleavage site sequence. A preferred polypeptide to be fused to the Epo coding sequence fragment is glutathione S-transferase, possessing a thrombin proteolytic cleavage site at the carboxyl terminus.

15

20

An expression vector for the invention disclosed herein expresses the EpoR extracellular domain as part of a fusion protein that can subsequently be cleaved to yield purified EpoR extracellular domain. The coding sequence for the EpoR extracellular domain may be engineered in any manner suitable for inserting the sequence in the appropriate reading frame in the expression vector. For example, a pair of polymerase chain reaction (PCR) primers may be synthesized, such that the first primer corresponds to the coding sequence at the 5' end of the extracellular domain and the second primer is complementary to the coding sequence of the 3' end of the extracellular domain. The primers preferably have convenient restriction enzyme sites flanking the portions of the primers corresponding to the ends of the desired target sequences. The primers are used to amplify the EpoR extracellular domain from a full length human EpoR cDNA template. The

25

30

resulting PCR product is then cloned into an expression vector. It is preferable to synthesize PCR primers having different restriction sites at each end, rather than the same restriction site. The presence of different restriction sites at each end of the PCR product facilitates the insertion of the human
5 EpoR coding sequence fragment in the sense orientation.

High level expression of a fusion protein having human erythropoietin receptor extracellular domain as part of the fusion protein is achieved by inducing expression from the recombinant plasmid expression vector in a host cell culture. A fusion protein is hereinafter referred to as
10 EpoRex-th and a purified human erythropoietin receptor extracellular domain hereinafter is referred to as Epo-bp. A cell protein extract is preferably prepared from an expressing E. coli culture in any suitable manner. EpoRex-th may be purified from the extract as desired. For example, the extract may be passed over a column having the ability to bind the portion of the fusion
15 protein upstream of the Epo-bp coding sequence. The fusion protein will bind to the column, while other proteins in the extract are eluted in column washes with a buffer that allows binding of fusion protein to the column matrix. EpoRex-th can be subsequently eluted in high purity by changing the buffer conditions.

20 Purification of Epo-bp may be accomplished by cleaving purified EpoRex-th using an appropriate cleavage method. For example, the cleavage site between the upstream polypeptide and Epo-bp may be sensitive to cyanogen bromide or, alternatively, may be sensitive to site-specific protease cleavage. In a preferred embodiment, a thrombin proteolytic cleavage site is
25 engineered into the upstream polypeptide, but 5' to the convenient restriction cloning sites positioned at the carboxyl terminus of the upstream polypeptide coding sequence.

The cleaved Epo-bp polypeptide segment may be separated from the upstream polypeptide segment by purification techniques such as size
30 exclusion chromatography, isoelectric focusing, or affinity chromatography. Furthermore, more than one purification technique may be used, if desired, to achieve the appropriate degree of purification. A preferred purification

technique is affinity chromatography. For example, a protease-treated fusion protein mixture may be applied to a column having agarose beads coupled to Epo. The cleaved Epo-bp segment will bind to the Epo-agarose, while the upstream polypeptide segment will pass through the column. Epo-bp may
5 then be eluted by lowering the pH of the liquid phase.

In an embodiment of the invention, the coding sequence for amino acids 25 through 250 of human EpoR (hEpoR) is cloned into pGEX-2T (Pharmacia, Mechanicsburg, PA). pGEX-2T has an IPTG inducible promoter operably linked to a coding sequence for glutathione S-transferase (GST). The
10 3' end of the GST coding sequence has a thrombin proteolytic cleavage site in the correct reading frame, as well as convenient cloning sites for inserting a coding sequence to be covalently coupled to GST.

A PCR product having amino acids 25 through 250 of hEpoR is made from a suitable DNA template, for example a full-length human EpoR
15 cDNA. A PCR primer is synthesized having the 5' end of the extracellular domain coding sequence as well as a BamHI site, and a PCR primer is synthesized having sequence complementary to the 3' end of the extracellular domain coding sequence as well as an EcoRI site. The BamHI site in pGEX-2T is positioned 5' to the EcoRI site relative to the GST coding sequence. The
20 PCR product is cloned into pGEX-2T, and a transformed *E. coli* colony having a plasmid of the expected size is identified.

A fusion protein having an amino terminal GST segment and a carboxy terminal EpoR extracellular domain segment is expressed in transformed *E. coli* by inducing transcription with IPTG. IPTG derepresses the
25 lac promoter positioned upstream of the fusion protein coding sequence. After allowing expression for a period of time sufficient to accumulate an amount of the fusion protein, cells are lysed and a crude extract is made in any suitable manner. The crude extract mixture has the fusion protein in addition to many other cellular proteins. The fusion protein, EpoRex-th, may
30 be purified from the extract as desired.

In a preferred embodiment, EpoRex-th is passed over a column having agarose beads coupled to glutathione (GSH). GSH is a substrate for

GST, and the GST segment of EpoRex-th will bind to the immobilized GSH with high affinity. Thus, the fusion protein becomes bound to the column, while virtually all other proteins in the extract will not bind. After washing, EpoRex-th may be eluted from the column by adding reduced GSH to the liquid phase.

In an embodiment of the invention, purified human erythropoietin receptor extracellular domain polypeptide may be made by digesting EpoRex-th with thrombin. The resulting digested mixture of GST and Epo-bp may then be applied to an Epo affinity column. The Epo-bp binds to its ligand, Epo, whereas GST passes through the column. Epo-bp may be eluted in purified form through use of an appropriate elution buffer, for example 0.1 M glycine, pH 3.0.

Antibodies to human erythropoietin receptor extracellular domain can be made by presentation of a purified preparation of such a polypeptide to the immune system of an animal. For example, purified Epo-bp may be injected subcutaneously, intramuscularly or intraperitoneally into animals such as rats, mice, rabbits, or sheep. Booster injections can be given at intervals, if desired. Circulating antibodies against Epo-bp are made by the immune system of the injected animal, and these antibodies can be collected from the blood, preferably from the serum. Anti-Epo-bp serum can be used to detect Epo-bp in various assay formats, such as Western blots, ELISA assays and the like. Epo-bp to be detected may be from, for example, a purified preparation of Epo-bp, a bacterial or eukaryotic cell extract, a eukaryotic cell from an in vitro cell culture, a serum sample, or even a tissue or cell biopsy taken from an individual. Anti-Epo-bp antibodies are expected to recognize the extracellular domain of intact human EpoR as well as Epo-bp. Monoclonal antibodies directed against Epo-bp can be made by methods known in the art. D'Andrea et al., Blood 75: 874-80 (1990); Goldwasser et al., U.S. Patent No. 4,558,005; Harlow and Lane, Antibodies - Lab Manual, Cold Spring Harbor Laboratory, 1988.

Antibodies directed against Epo-bp preferably have a specific binding affinity for the EpoR extracellular domain. For example, serum from

an animal injected with purified Epo-bp should provide detectable binding to Epo-bp in Western blots when 10 µg of purified Epo-bp are electrophoresed in a polyacrylamide gel and exposed to a 1:2000 dilution of the anti-Epo-bp serum.

5 The purified extracellular domain of EpoR disclosed herein is the first such pure human Epo receptor fragment (i.e., free of non-human or non-Epo receptor amino acid sequence) to be obtained. The experiments disclosed herein demonstrate that such a fragment retains the ability to specifically bind human Epo. The proteins and antibodies disclosed herein
10 are useful for understanding the mechanisms of Epo - Epo receptor interaction. The purified Epo-bp of the present invention is also useful for investigating the structure of the Epo receptor and for identifying factors involved in regulating differentiation and proliferation mechanisms in erythroid progenitor cells. Moreover, the invention disclosed herein is
15 useful for identifying and quantitating Epo and Epo receptor, as well as in understanding hematopoietic malignancy and certain cardiovascular system disorders. That is, increased/decreased hematocrit and/or hemoglobin levels may affect blood pressure and cause other circulatory problems.

 The invention will be further understood with reference to the
20 following illustrative embodiments, which are purely exemplary, and should not be taken as limiting the true scope of the present invention as described in the claims.

EXAMPLE 1

25 Materials

 Glutathione (GSH)-agarose, pGEX-2T expression vector and Sephadex G-50 were purchased from Pharmacia (Mechanicsburg, PA). PCR reagents were from Perkin-Elmer Cetus (Norwalk, CT) and Affigel 15 was from BioRad (Richmond, CA). Bacteriophage T4 DNA ligase, restriction
30 enzymes and isopropylthio-β-D-galactoside (IPTG) were purchased from BRL Gibco (Gaithersburg, MD). Geneclean II was from Bio 101, La Jolla, CA.

Nitrocellulose was from Schleicher & Schuell Co. (Keene, NH). Chemiluminescence (ECL) reagents and ^{125}I -Epo were from Amersham (Arlington Heights, IL) and unlabeled Epo was a gift of Chugai-Upjohn (Rosemont, IL). Phenylmethylsulfonylfluoride (PMSF),
5 diisopropylfluorophosphate (DFP), thrombin, trypsin and Triton X-100, were from Sigma Chemical Company (St. Louis, MO). Biotinylated rabbit anti-sheep antibodies and avidin-horseradish peroxidase were from Pierce Co. (Rockford, IL). LAP37, a full-length human erythropoietin receptor (EpoR) cDNA preparation, was provided by Dr. Bernard G. Forget, Yale University,
10 New Haven, CT. All other chemicals were of reagent grade.

EXAMPLE 2

Construction of EpoR cDNA Recombinant Vector

A recombinant plasmid expression vector, pJYL26, was
15 constructed from a PCR product having the human Epo receptor extracellular domain coding sequence and from the plasmid vector pGEX-2T. The construction of this plasmid is explained below.

PCR amplification was carried out using a full-length human EpoR cDNA, LAP37, as a template. The 5'-sense primer was 5'-
20 TTGGATCCGCGCCCCCGCCTAAC-3'. This primer has a BamH1 linker sequence at the 5' end, followed by the coding sequence for amino acids 25 through 29 of the full length human EpoR protein. The 3'-antisense primer was 5'-TGAATTCGGGGTCCAGGTCGCT-3'. This primer has an EcoR1 linker followed by sequence complementary to the coding sequence for amino acids
25 226 through 222 of full length EpoR. Using a Perkin Elmer-Cetus PCR kit, PCR was carried out with 0.1 μg of LAP37 cDNA, 20 pM of each primer, 1.25 mM dNTP mixture (dGTP, dCTP, dTTP and dATP), 0.5 μl of Taq polymerase, and 10x buffer supplied in the PCR kit. Amplification was carried out by a PTC-100 Programmable Thermal Controller, (M.J. Research, Inc. Watertown,
30 MA), with denaturation at 94°C for 1 min, annealing at 55°C for 1 min and extension at 72°C for 1 1/2 min, repeated for 25 cycles.

The sizes of the PCR product (~600 bp) and pGEX-2T (~4.9 kb) were verified on 1% Seakem and 2% Nusieve agarose (FMC Bioproducts, Rockland, ME) gels running in 1x TA buffer (50x TA in 1 liter volume containing 242 g Tris-base and 57.1 ml acetic acid), with a Hae II standard.

5 Both the PCR product and pGEX-2T were purified from gel slices by the GeneClean II method as described by the manufacturer (Bio 101, La Jolla, CA). Concentrations of the PCR product and pGEX-2T were estimated by absorbance readings at OD260. Both DNAs were then digested with BamHI and EcoRI for 4 hours at 37°C before ligation. The digested products were

10 analyzed on 1% Seakem and 2% Nusieve agarose gels. Both the PCR product and pGEX-2T fragments were cut from the gel and purified again by the GeneClean II method.

The ligation was done in a mixture having 1 µg/µl each of PCR product and pGEX-2T. The mixture was incubated at 45°C for 5 minutes and

15 chilled to 0°C. Then, in a 10 µl final volume, 1 µl each of 10x bacteriophage T4 DNA buffer and 10x bacteriophage DNA ligase, and 10 mM ATP were added. The whole mixture was then incubated at 16°C in a circulating water bath overnight. Productive ligation was verified by electrophoresis in a 1% agarose gel in 1x TA buffer running at 100 volts with lanes containing size

20 standards, pGEX-2T, PCR product, and the ligated product (PCR product + pGEX-2T). The ligated product was verified to be ~5.5 kb. An aliquot of ligation mixture was then transformed into E. coli strain JM109 (20 µg ligation mixture/200 µl JM109). For the transformation, the E. coli mixture was incubated on ice for 30 minutes after mixing gently by inverting, and

25 incubated at 42°C exactly 90 seconds. Then the mixture was chilled on ice for 1-2 minutes and 500 µl LB medium (for 1 liter, 10 g bacto-tryptone, 5 g bacto-yeast and 10 g NaCl, pH 7.5, autoclave) was added. After incubating at 37°C for 45 minutes, the LB mixtures were spread on LB/Amp agar petri plates in amounts of 50, 75, 125, 150, and 300 µl of LB mixture. Agar petri plates were

30 prepared with 20-30 ml of LB/Amp medium, containing 15 g agar/liter LB (autoclaved) and 100 µg/liter ampicillin. Control LB/Amp plates were made

with intact pGEX-2T, digested pGEX-2T and PCR product only. The plates were kept on the bench top to absorb liquid for a few hours and inverted plates were incubated at 37°C for 24 hours. Grown colonies were seeded on gridded plates, which were incubated again at 37°C for 24 hours, while
5 another set of all colonies was grown in 5 ml each of the LB/Amp medium overnight.

The DNA was extracted from each colony by the miniprep method. Each colony was cultured overnight with 5 ml LB/Amp medium (2 µl/ml of 50 µg/ml Amp stock) in a loosely capped 15-ml plastic tube in a
10 vigorously shaking 37°C incubator. The following day, 1.5 ml of each culture was pelleted in a microfuge for 3 minutes at 4°C at 14,000 x g, and resuspended in 93 µl STET plus 17 µl of lysozyme stock (STET: 5% sucrose + 5% Triton X-100 + 50 mM Tris, pH 8.0 + 50 mM EDTA, pH 8.0, stored at 4°C; lysozyme stock: 5 mg/ml, stored in a freezer). The resuspended mixture was
15 then incubated for 10 minutes at room temperature and boiled for 2 minutes before spinning in a microfuge at 4°C for 15 minutes at 14,000 x g. The pellet was removed with a sterile tooth pick, 2 µl of RNase (100 mg/ml) was added to the supernatant, followed by incubation at 37°C for 30 minutes. After incubation, 110 µl of ice-cold isopropanol was added and the mixture was
20 inverted 4 times before pelleting at 14,000 x g, 4°C for 15 minute. The pellet (DNA) was then washed with ~1 ml of 70% ethanol to remove residual STET and other contaminants, and the pellet centrifuged again at 14,000 x g, 4°C for 15 minutes. The pellet was then air dried for 1-2 hours and resuspended in 25 µl of sterile dH₂O.

25 The extracted DNAs were verified on a 0.8% agarose gel in TA buffer, running at 100 volts until the front dye line migrated 4/5 of the length of the gel. The gel was stained with ethidium bromide (0.5 µg/ml) at room temperature for 15 minutes on a gentle shaker and destained with dH₂O for 15 minutes. DNA bands were examined under UV light. Cultures having DNA
30 of the expected size were examined in 1% agarose gels running in TA buffer after EcoR1 and/or EcoR1 plus BamH1 digestion. The EcoR1 and BamH1 digestion was done by incubating the sample mixture at 37°C water bath for 2

hours with the mixture of 1 μ g of EcoR1 or BamH1 per 2 μ g of DNA in 1 μ l/10 μ l sample volume of 10x reaction buffer provided in the restriction enzyme kit. One colony having a plasmid of about ~5.5 kb in size was selected after examining both EcoR1 and EcoR1 plus BamH1 digested DNA sizes in 1% agarose gels. The plasmid in this colony was named pJYL26. A diagram of pJYL26 is shown in the upper part of Figure 1.

EXAMPLE 3

Purification of EpoRex-th Fusion Protein

This example teaches the production and purification of a fusion protein having two segments. The first segment is a polypeptide, GST, with a thrombin cleavage site at the carboxyl terminus. The second segment, fused to the first segment at the thrombin cleavage site, is the extracellular domain of human Epo receptor. The fusion protein EpoRex-th, containing GST and Epo-bp, is purified by GSH-agarose affinity chromatography.

Transformed *E. coli* containing the recombinant vector pJYL26 were grown overnight at 37°C with vigorous shaking in 400 ml of LB medium with 100 μ g/ml of ampicillin. The following day, the culture was diluted in 4 liters of fresh LB/Amp media and incubated for another 90 min before adding 1 mM isopropylthio- β -D-galactoside (IPTG). After 4 hours of IPTG induction, the cells were pelleted at 3,000 x g at 4°C for 15 min and resuspended in 160 ml of lysis buffer, containing 50 mM sodium phosphate, pH 7.4, 10 mM β -mercaptoethanol (β ME), 10 mM EDTA, pH 8.0, 1 mM PMSF and 1 mM DFP. 160 mg of solid lysozyme was then added. Using a 60 cc syringe, the lysed cell suspension was homogenized by passing through 18, 21 and 23 gauge needles three times, and incubated on ice 30 min. After dry ice/methanol freeze thaw at 37°C for 3 times and mild sonication, 1% of Triton X-100 was added. The supernatant was collected by centrifugation 15 x kg at 4°C for 15 min.

A GSH-agarose column was prepared by washing swollen GSH-agarose beads 3 times with 10 bed volumes of phosphate-buffered saline (PBS:

16 mM Na_2HPO_4 , 4 mM NaH_2PO_4 , pH 7.4 in excess salt of 3 M NaCl) to remove preservatives and elutable dextran from the agarose. The column was then equilibrated with 5 bed volumes of isotonic PBS. The IPTG induced extract was applied to the column and the column was washed twice with 5
5 bed volumes of PBS, which elutes all proteins with no affinity for GSH-agarose. EpoRex-th was then eluted by adding 5 bed volumes of elution buffer, containing 5 mM reduced GSH in 50 mM Tris-HCl, pH 8.0. Fractions of 1.0 ml were collected and the A_{280} was determined for each fraction. Figure 2a shows the A_{280} data. Fractions 18-23 were subsequently shown to have the
10 EpoRex-th protein. These fractions were pooled. From a four-liter cell culture preparation, an average of 2 mg of EpoRex-th was extracted.

EXAMPLE 4

Purification of Epo-bp

15 EpoRex-th contains a thrombin-specific proteolytic cleavage site, as diagrammed in the lower half of Figure 1. Thrombin cleaves specifically at the sequence -CTG GTT CCG CGT GGA TCC-, which codes for the amino acids Leu Val Pro Arg Gly Ser, as shown in Figure 1. Smith and Johnson, Gene 67:31-40 (1988). Thrombin was incubated with EpoRex-th to cleave the
20 GST segment from the Epo-bp segment and the two segments were purified by Epo-agarose affinity, as described below.

Various thrombin concentrations were tested in order to find the most effective range of thrombin cleavage. Purified EpoRex-th was incubated with 0.0125, 0.125, 0.6 or 2.4 μg of thrombin per 60 μg EpoRex-th at
25 room temperature or 37°C for 1 hour in PBS buffer, pH 7.4. The results were analyzed by polyacrylamide gel (12.5%) electrophoresis. After staining with Coomassie blue, bands could be seen corresponding to the fusion protein EpoRex-th (55 kDa), Epo-bp (29 kDa) and GST (26 kDa). The 0.6 μg concentration was selected for complete digestion of EpoRex-th. The results
30 are presented in Figures 3.

For thrombin cleavage, 60 μ g of EpoRex-th was incubated at room temperature for 1 hr with 0.6 μ g thrombin. The mixture was applied to an erythropoietin - agarose column in Tris buffered saline (TBS) or PBS. Epo-bp was eluted with 0.1 M glycine buffer, pH 3.0. Fractions of 0.5 ml were
5 collected into tubes, containing 0.5 ml of 2 M Tris-HCl, pH 7.5. Epo-bp peak fractions 14-19 were pooled and then dialyzed overnight in TBS or PBS at 4°C for further experiments. Approximately 200 μ g Epo-bp was extracted, starting from a four-liter cell culture preparation.

The Epo-agarose column was prepared from Epo-agarose beads.
10 The Epo-agarose beads were prepared by overnight dialysis of Epo (0.5 mg/ml) in 0.1 M 3(N-morpholino)-propanesulfonic acid (MOPS) at 4°C. Epo was linked to Affigel 15 beads by admixing 1 ml of the dialyzed Epo-solution and 2 ml of washed Affigel 15, and incubated at room temperature for 2 hours on a rotating shaker. The supernatant was removed after microcentrifuging at
15 2000 x g for 30 sec. The packed Epo-agarose beads were washed 3 times in TBS or PBS at 4°C and stored until ready to use. After collecting desired protein fractions, Epo-agarose beads may be washed extensively with TBS or PBS and stored at 4°C for reuse.

20

EXAMPLE 5

Production of Antibodies to Epo-bp

This example teaches the production of antibodies directed against purified Epo-bp. Purified Epo-bp is electrophoresed in a 12.5% SDS-PAGE gel and the Epo-bp protein band is resuspended in PBS and injected
25 into sheep. Sheep serum having anti-Epo-bp antibody is shown to detect purified human Epo-bp when the serum is diluted 1:2000.

Epo-bp (0.5 mg), purified as described above, was mixed with 2x treatment (Laemmli) buffer and boiled for 10 minutes. The mixture was applied to a 12.5% SDS gel and electrophoresed at 200 volts for 3-4 hours. The
30 gel was stained with 0.125% Coomassie blue overnight, destained 1-2 hours with dH₂O, and the Epo-bp band cut out of the gel with a razor blade.

The Epo-bp gel slice was resuspended in 10-15 ml of PBS buffer and passed through a syringe repeatedly until the gel was crushed into small pieces forming a suspension mixture with PBS. The suspension was injected subcutaneously in adult sheep. Epo-bp was injected at a ratio of 0.5 mg Epo-bp or more per 25 kg weight of the animal. Two booster injections, with the same dose as in the initial injection, were given once every 3 weeks following initial injection. After the second booster injection, blood can be withdrawn for collection of antibodies. Injections can be given every month to maintain antibody production by the animal. Injection sites are rotated on the animal.

10 Sambrook et al., Molecular Cloning, 2nd Ed., Cold Spring Harbor Laboratory Press, Chapter 18, 1989.

To obtain blood from injected animals, hair at the blood sampling site was cleaned with 70% alcohol. Ear arteries or other accessible arteries were shaved over. A small amount of xylene was applied to the tip of the ear but not at the bleeding site. Blood was gently withdrawn with a butterfly and put into a glass tube having no heparin. The blood was incubated at room temperature for 1 hour to allow clotting, the clot was loosened from the tube wall with a pasteur pipet, and the tube was incubated at 4°C overnight. The clotted blood mixture was poured into a dish and the clot removed. The unclotted remainder was returned to the glass tube and centrifuged at 3000 rpm for 10 minutes. The supernatant (serum) was applied to an Epo-bp-affinity column and antibodies binding to the column were eluted by with 0.1 M glycine buffer, pH 3.0, using the same procedures as discussed above for purification of Epo-bp. The eluate was dialyzed in PBS overnight at 4°C and stored at -70°C in 500 µl aliquots. The Epo-bp affinity column was prepared from Epo-bp and Affigel 15 agarose beads in the same manner as the Epo-bp Affigel beads described in Example 6 below.

Solutions used in this example are prepared as follows:

Lysis Buffer II: 50 mM NaPO₄ (7.74 ml of 0.5 M dibasic PO₄ plus 2.26 of 0.5 M monobasic PO₄) + 10 mM β-mercaptoethanol + 10 mM EDTA, pH 8.

PBS Buffer: 0.15 M NaCl + 16 mM dibasic PO₄ + 6 mM monobasic PO₄, pH 7.4.

TBS buffer: for 1 liter, 12.5 ml of 2 M Tris-HCl, pH 7.4 + 27.5 ml of 5 M NaCl.

2x Treatment (Laemmli) buffer: 0.125 M Tris-HCl, pH 6.8 + 4% SDS + 20% glycerol + 10% beta-mercaptoethanol.

Sheep anti-Epo-bp serum was analyzed for binding to purified
5 Epo-bp by Western blotting as described in Sambrook et al., Molecular Cloning, 2nd Ed., Cold Spring Harbor Laboratory Press, 1989 and in Western blotting protocols provided by the ECL manufacturer, Amersham Co., Arlington Heights, IL. Following thrombin cleavage, EpoRex-th and Epo-bp were separated electrophoretically on an SDS-PAGE gel. The gel was then
10 blotted onto nitrocellulose (Schleicher and Schuell Co., Keene, NH). Sheep anti-Epo-bp serum was added to the nitrocellulose in Blotto (for 1 liter: 80 g non-fat dry milk, 30 ml 5M NaCl, 10 ml 2M Tris-HCl, pH 7.5 and 0.05% Tween-20) at a 1:2000 dilution and incubated at room temperature for 1 hour with gentle agitation. After rinsing off the first antibody, a second reagent,
15 biotinylated rabbit anti-immunoglobulin anti-sheep (1:10,000 dilution) antibody was added to the nitrocellulose in Blotto, and incubated at room temperature for another 1 hour with rocking. Horseradish peroxidase-avidin (1:10,000 dilution) was added and the mixture incubated at room temperature for 45 min. After soaking the washed nitrocellulose briefly in
20 chemiluminescence (ECL) reagents, wet blots were exposed immediately on KODAK X-ray film. Figure 4 shows a photograph of the Western blot, with the lanes having the following proteins applied: Lane 1, molecular weight standards; Lane 2, thrombin digested EpoRex-th; Lane 3, GST; Lane 4, purified Epo-bp. As shown in lane 4 of Figure 4, purified Epo-bp was detected by a
25 1:2000 dilution of anti-Epo-bp antibody. The apparent molecular weight of the purified Epo-bp was about 29 kDa.

EXAMPLE 6

Binding of Epo to Epo-bp

30 Ligand binding of Epo to Epo-bp and effects of Epo concentration on binding are taught in this example.

Epo-bp beads were prepared by adding 60 $\mu\text{g/ml}$ Epo-bp to washed Affigel 15 agarose beads in PBS, with a final concentration of approximately 30 μg of protein per 1 ml of Epo-bp beads. The mixture was incubated at room temperature for 2 hours on a rotating platform. After washing 3 times with ice cold PBS buffer, the pellet was resuspended in 1 ml of PBS buffer. For binding assays, 30 μl of the final suspension (approximately 1.0 μg of Epo-bp) were admixed with various concentrations of ^{125}I -Epo and incubated for 1 hour at room temperature while resuspending every 5 min with a pipet. At the end of the incubation, 1 ml of ice cold PBS buffer was added to wash out unreacted ^{125}I -Epo and the wash was repeated twice more. The reacted beads were counted by a gamma counter. Proteins smaller than the intact Epo-bp from trypsin digested extracts (see below) were also applied in the same way to test any effect on ligand binding. Nonspecific binding was measured by the same method except the mixture was preincubated with a 200-fold excess of unlabeled Epo for 1 hour prior to adding labeled Epo.

Binding of Epo-bp to Epo is shown in Figure 5. Each point in Figure 5 is the mean of 2-4 samples. Data are expressed as mean \pm SEM. A p value of less than 0.05 was considered significant. Results were analysed with the two-tailed Student t -test. The specific binding activity of Epo to Epo-bp dramatically increased as Epo concentration increased; the binding tripled from 8 nM to 12 nM ^{125}I -Epo. Apparent saturation of Epo binding occurred at 12 nM. This was also confirmed in the unreacted supernatant of ^{125}I -Epo. Binding of ^{125}I -Epo to Epo-bp was significantly inhibited in the presence of unlabeled Epo at concentrations of 8 nM and higher of ^{125}I -Epo ($p < 0.0001$ in both comparisons). Nonspecific binding was somewhat higher than expected. It had been expected that the excess unlabeled Epo might eliminate ^{125}I -Epo binding completely because of the sensitivity and specificity of Epo binding to Epo-bp shown in Western blots and binding assays.

Trypsin digestion experiments were performed to find a minimum sequence of Epo-bp involved in ligand binding. There are several arginine and lysine sites in the Epo receptor protein, which may be specific

sites for trypsin digestion. Trypsin digestion of Epo-bp was carried out at 10, 20, 30, 50, 100 μ g and 2 mg of trypsin per 5 μ g of Epo-bp in a total volume of 200 μ l in PBS, pH 6.7 at 37°C for 3 or 6 hours. The reaction was stopped by adding the same volume of 2 N acetic acid or by boiling. As shown in Figure 6, Epo-bp was cleaved effectively when 20 μ g or more of trypsin was present. Trypsin is visible as a 23.2 kDa protein band in the lane having 2 mg of trypsin. The trypsin digested Epo-bp is visible as a 20-kDa protein. In Figure 6, Lane 1 contains standard molecular weight markers; lane 2 is a control; lanes 3-8 represent digestions at concentrations of 10, 20 30, 50, 100 μ g and 2 mg trypsin, respectively at 37°C for 3 hours; lanes 9-14 represent the same concentrations of trypsin incubated at 37°C for 6 hours.

Since uncut Epo-bp is approximately 30 kDa, gel filtration chromatography using Pharmacia Sephadex G-50 (MW \leq 30,000) was applied to separate protein components of size \leq 30,000 molecular weight from the total mixture. A powdered form of Sephadex G-50 was hydrated and washed several times with isotonic PBS to wash out preservatives. Trypsin digested EpoRex-th was applied to the top of the gel column in a total volume of 0.2 ml in PBS. The column was centrifuged at 2,000 x g for 4 min at room temperature in a swinging-bucket rotor. The first effluent was collected from the bottom of the syringe (~0.2 ml) into a decapped microfuge tube. This effluent contains proteins having a size larger than Epo-bp. Another 0.2 ml of PBS buffer was added to the column and a second eluate collected into a new decapped microfuge by recentrifuging for 10 min. This step was repeated twice. The second eluate was applied to an Epo-agarose column and peak fractions were examined by SDS-PAGE gels and Western blotting. The final product of Epo-bp, as a result of trypsin digestion, was approximately 20 kDa, shown in Figure 6. The antibody did not recognize the cleaved Epo-bp. Thus, deletion of 30 amino acids from Epo-bp by trypsin digestion completely eliminated recognition by antibodies to Epo-bp, as verified by Western blotting.

The foregoing detailed description has been provided for a better understanding of the invention only and no unnecessary limitation should be understood therefrom as some modifications will be apparent to those skilled in the art without deviating from the spirit and scope of the appended

5 claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- 5 (i) APPLICANT: Jong Y. Lee
- (ii) TITLE OF INVENTION: PURIFIED HUMAN ERYTHROPOIETIN
RECEPTOR PROTEIN FRAGMENT AND ANTIBODIES DERIVED THEREFROM
- 10 (iii) NUMBER OF SEQUENCES: 4
- (iv) CORRESPONDENCE ADDRESS
- (A) ADDRESSEE: Patterson & Keough, P.A.
- 15 (B) STREET: 527 Marquette Avenue South
- (C) CITY: Minneapolis
- 20 (D) STATE: Minnesota
- (E) COUNTRY: USA
- (F) ZIP: 55402
- 25 (v) COMPUTER READABLE FORM
- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: Apple Macintosh
- 30 (C) OPERATING SYSTEM: Apple Macintosh System 7.0
- (D) SOFTWARE: Macintosh Text File
- 35 (vi) CURRENT APPLICATION DATA
- (A) APPLICATION NUMBER:
- (B) FILING DATE:
- 40 (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA
- (A) APPLICATION NUMBER: U.S. 08/106,815
- 45 (B) FILING DATE: 16-AUG-93
- (viii) ATTORNEY/AGENT INFORMATION
- (A) NAME: Mark S. Ellinger
- 50 (B) REGISTRATION NUMBER: 34,812
- (C) REFERENCE/DOCKET NUMBER: 1226.01-WO-01
- 55 (ix) TELECOMMUNICATION INFORMATION
- (A) TELEPHONE: 612/349-5740

(B) TELEFAX: 612/349-9266

5 (2) INFORMATION FOR SEQ ID NO: 1

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 23

10 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single stranded

15 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: synthetic DNA

(A) DESCRIPTION:

20 (iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE:

25 (vi) ORIGINAL SOURCE:

(A) ORGANISM:

(B) STRAIN:

30 (C) INDIVIDUAL ISOLATE:

(vii) IMMEDIATE SOURCE:

(A) LIBRARY:

35 (B) CLONE:

(viii) POSITION IN GENOME

(A) CHROMOSOME/SEGMENT

40 (ix) FEATURE:

(A) NAME/KEY: BamH1 linker at 5' end followed by
sequence for amino acids 25 through 29 of the full length human
EpoR protein. Forward primer for Sequence ID No. 2.

45 (x) PUBLICATION INFORMATION:

(A) AUTHORS:

(B) TITLE:

50 (C) JOURNAL:

(D) VOLUME:

55 (E) ISSUE:

(F) PAGES:

(G) DATE:

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1

TTGGATCC GCG CCC CCG CCT AAC 23
Ala Pro Pro Pro Asn

10 (2) INFORMATION FOR SEQ ID NO: 2

(i) SEQUENCE CHARACTERISTICS

15 (A) LENGTH: 22

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single stranded

20 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: synthetic DNA

(A) DESCRIPTION:

25 (iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

30 (v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(A) ORGANISM:

35 (B) STRAIN:

(C) INDIVIDUAL ISOLATE:

(vii) IMMEDIATE SOURCE:

40 (A) LIBRARY:

(B) CLONE:

(viii) POSITION IN GENOME

45 (A) CHROMOSOME/SEGMENT

(ix) FEATURE:

(A) NAME/KEY: EcoR1 linker followed by sequence
complementary to coding sequence for amino acids 226 through
222 of full length human EpoR protein. Reverse primer for
50 Sequence ID No. 1.

(x) PUBLICATION INFORMATION:

(A) AUTHORS:

55 (B) TITLE:

25

(C) JOURNAL:
(D) VOLUME:
5 (E) ISSUE:
(F) PAGES:
10 (G) DATE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2
TGAATTCGGG GTCCAGGTCG CT 22
15 (2) INFORMATION FOR SEQ ID NO: 3

(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 18
20 (B) TYPE: nucleic acid
(C) STRANDEDNESS: double stranded
25 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION:

30 (iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(v) FRAGMENT TYPE:
35 (vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens
40 (B) STRAIN:
(C) INDIVIDUAL ISOLATE:

(vii) IMMEDIATE SOURCE:
45 (A) LIBRARY:
(B) CLONE: pGEX-2T, Pharmacia (Mechanicsburg, PA)

(viii) POSITION IN GENOME
50 (A) CHROMOSOME/SEGMENT

(ix) FEATURE:
(A) NAME/KEY: Thrombin Cleavage Site in plasmid
55 vector pGEX-2T

(x) PUBLICATION INFORMATION:

(A) AUTHORS: Smith, D.B. and Johnson, K.S.

5 (B) TITLE: Single-step purification of polypeptides
expressed in Escherichia coli as fusions with
glutathione-S-transferase.

(C) JOURNAL: Gene

10 (D) VOLUME: 67

(E) ISSUE:

15 (F) PAGES: 31-40

(G) DATE: 1988

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3

20 CTG GTT CCG CGT GGA TCC 18
Leu Val Pro Arg Gly Ser

5

(2) INFORMATION FOR SEQ ID NO: 4:

25 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1527

30 (B) TYPE: nucleic acid

(C) STRANDEDNESS: double stranded

(D) TOPOLOGY: linear

35 (x) PUBLICATION INFORMATION:

(A) AUTHORS: Winkelmann, J. C., et al.

40 (B) TITLE:

(C) JOURNAL: Blood

(D) VOLUME: 76

45 (E) ISSUE: 1

(F) PAGES: 24-30

50 (G) DATE: 1990

(x) PUBLICATION INFORMATION:

55 (A) AUTHORS: Jones, S. S., et al.

(B) TITLE:

(C) JOURNAL: Blood

5 (D) VOLUME: 76

(E) ISSUE: 1

(F) PAGES: 31-35

10 (G) DATE: 1990

(x) PUBLICATION INFORMATION:

15 (A) AUTHORS: Noguchi, C.T., et al.

(B) TITLE:

(C) JOURNAL: Blood

20 (D) VOLUME: 78

(E) ISSUE: 10

25 (F) PAGES: 2548-2556

(G) DATE: 1991

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

30 ATG GAC CAC CTC GGG GCG TCC CTC TGG CCC CAG GTC GGC TCC CTT 45
Met Asp His Leu Gly Ala Ser Leu Trp Pro Gln Val Gly Ser Leu
5 10 15

35 TGT CTC CTG CTC GCT GGG GCC GCC TGG GCG CCC CCG CCT AAC CTC 90
Cys Leu Leu Leu Ala Gly Ala Ala Trp Ala Pro Pro Pro Asn Leu
20 25 30

40 CCG GAC CCC AAG TTC GAG AGC AAA GCG GCC TTG CTG GCG GCC CGG 135
Pro Asp Pro Lys Phe Glu Ser Lys Ala Ala Leu Leu Ala Ala Arg
35 40 45

45 GGG CCC GAA GAG CTT CTG TGC TTC ACC GAG CGG TTG GAG GAC TTG 180
Gly Pro Glu Glu Leu Leu Cys Phe Thr Glu Arg Leu Glu Asp Leu
50 55 60

GTG TGT TTC TGG GAG GAA GCG GCG AGC GCT GGG GTG GGC CCG GGC 225
Val Cys Phe Trp Glu Glu Ala Ala Ser Ala Gly Val Gly Pro Gly
65 70 75

50 AAC TAC AGC TTC TCC TAC CAG CTC GAG GAT GAG CCA TGG AAG CTG 270
Asn Tyr Ser Phe Ser Tyr Gln Leu Glu Asp Glu Pro Trp Lys Leu
80 85 90

55 TGT CGC CTG CAC CAG GCT CCC ACG GCT CGT GGT GCG GTG CGC TTC 315

	Cys	Arg	Leu	His	Gln	Ala	Pro	Thr	Ala	Arg	Gly	Ala	Val	Arg	Phe	
					95					100					105	
5	TGG	TGT	TCG	CTG	CCT	ACA	GCC	GAC	ACG	TCG	AGC	TTC	GTG	CCC	CTA	360
	Trp	Cys	Ser	Leu	Pro	Thr	Ala	Asp	Thr	Ser	Ser	Phe	Val	Pro	Leu	
					110					115					120	
10	GAG	TTG	CGC	GTC	ACA	GCA	GCC	TCC	GGC	GCT	CCG	CGA	TAT	CAC	CGT	405
	Glu	Leu	Arg	Val	Thr	Ala	Ala	Ser	Gly	Ala	Pro	Arg	Tyr	His	Arg	
					125					130					135	
15	GTC	ATC	CAC	ATC	AAT	GAA	GTA	GTG	CTC	CTA	GAC	GCC	CCC	GTG	GGG	450
	Val	Ile	His	Ile	Asn	Glu	Val	Val	Leu	Leu	Asp	Ala	Pro	Val	Gly	
					140					145					150	
	CTG	GTG	GCG	CGG	TTG	GCT	GAC	GAG	AGC	GGC	CAC	GTA	GTG	TTG	CGC	495
	Leu	Val	Ala	Arg	Leu	Ala	Asp	Glu	Ser	Gly	His	Val	Val	Leu	Arg	
					155					160					165	
20	TGG	CTC	CCG	CCG	CCT	GAG	ACA	CCC	ATG	ACG	TCT	CAC	ATC	CGC	TAC	540
	Trp	Leu	Pro	Pro	Pro	Glu	Thr	Pro	Met	Thr	Ser	His	Ile	Arg	Tyr	
					170					175					180	
25	GAG	GTG	GAC	GTC	TCG	GCC	GGC	AAC	GGC	GCA	GGG	AGC	GTA	CAG	AGG	585
	Glu	Val	Asp	Val	Ser	Ala	Gly	Asn	Gly	Ala	Gly	Ser	Val	Gln	Arg	
					185					190					195	
30	GTG	GAG	ATC	CTG	GAG	GGC	CGC	ACC	GAG	TGT	GTG	CTG	AGC	AAC	CTG	630
	Val	Glu	Ile	Leu	Glu	Gly	Arg	Thr	Glu	Cys	Val	Leu	Ser	Asn	Leu	
					200					205					210	
35	CGG	GGC	CGG	ACG	CGC	TAC	ACC	TTC	GCC	GTC	CGC	GCG	CGT	ATG	GCT	675
	Arg	Gly	Arg	Thr	Arg	Tyr	Thr	Phe	Ala	Val	Arg	Ala	Arg	Met	Ala	
					215					220					225	
	GAG	CCG	AGC	TTC	GGC	GGC	TTC	TGG	AGC	GCC	TGG	TCG	GAG	CCT	GTG	720
	Glu	Pro	Ser	Phe	Gly	Gly	Phe	Trp	Ser	Ala	Trp	Ser	Glu	Pro	Val	
					230					235					240	
40	TCG	CTG	CTG	ACG	CCT	AGC	GAC	CTG	GAC	CCC	CTC	ATC	CTG	ACG	CTC	765
	Ser	Leu	Leu	Thr	Pro	Ser	Asp	Leu	Asp	Pro	Leu	Ile	Leu	Thr	Leu	
					245					250					255	
45	TCC	CTC	ATC	CTC	GTG	GTC	ATC	CTG	GTG	CTG	CTG	ACC	GTG	CTC	GCG	810
	Ser	Leu	Ile	Leu	Val	Val	Ile	Leu	Val	Leu	Leu	Thr	Val	Leu	Ala	
					260					265					270	
50	CTG	CTC	TCC	CAC	CGC	CGG	GCT	CTG	AAG	CAG	AAG	ATC	TGG	CCT	GGC	855
	Leu	Leu	Ser	His	Arg	Arg	Ala	Leu	Lys	Gln	Lys	Ile	Trp	Pro	Gly	
					275					280					285	
55	ATC	CCG	AGC	CCA	GAG	AGC	GAG	TTT	GAA	GGC	CTC	TTC	ACC	ACC	CAC	900
	Ile	Pro	Ser	Pro	Glu	Ser	Glu	Phe	Glu	Gly	Leu	Phe	Thr	Thr	His	
					290					295					300	

	AAG GGT AAC TTC CAG CTG TGG CTG TAC CAG AAT GAT GGC TGC CTG	945
	Lys Gly Asn Phe Gln Leu Trp Leu Tyr Gln Asn Asp Gly Cys Leu	
	305 310 315	
5	TGG TGG AGC CCC TGC ACC CCC TTC ACG GAG GAC CCA CCT GCT TCC	990
	Trp Trp Ser Pro Cys Thr Pro Phe Thr Glu Asp Pro Pro Ala Ser	
	320 325 330	
10	CTG GAA GTC CTC TCA GAG CGC TGC TGG GGG ACG ATG CAG GCA GTG	1035
	Leu Glu Val Leu Ser Glu Arg Cys Trp Gly Thr Met Gln Ala Val	
	335 340 345	
15	GAG CCG GGG ACA GAT GAT GAG GGC CCC CTG CTG GAG CCA GTG GGC	1080
	Glu Pro Gly Thr Asp Asp Glu Gly Pro Leu Leu Glu Pro Val Gly	
	350 355 360	
20	AGT GAG CAT GCC CAG GAT ACC TAT CTG GTG CTG GAC AAA TGG TTG	1125
	Ser Glu His Ala Gln Asp Thr Tyr Leu Val Leu Asp Lys Trp Leu	
	365 370 375	
	CTG CCC CGG AAC CCG CCC AGT GAG GAC CTC CCA GGG CCT GGT GGC	1170
	Leu Pro Arg Asn Pro Pro Ser Glu Asp Leu Pro Gly Pro Gly Gly	
	380 385 390	
25	AGT GTG GAC ATA GTG GCC ATG GAT GAA GGC TCA GAA GCA TCC TCC	1215
	Ser Val Asp Ile Val Ala Met Asp Glu Pro Ser Glu Ala Ser Ser	
	395 400 405	
30	TGC TCA TCT GCT TTG GCC TCG AAG CCC AGC CCA GAG GGA GCC TCT	1260
	Cys Ser Ser Ala Leu Ala Ser Lys Pro Ser Pro Glu Gly Ala Ser	
	410 415 420	
35	GCT GCC AGC TTT GAG TAC ACT ATC CTG GAC CCC AGC TCC CAG CTC	1305
	Ala Ala Ser Phe Glu Tyr Thr Ile Leu Asp Pro Ser Ser Gln Leu	
	425 430 435	
	TTG CGT CCA TGG ACA CTG TGC CCT GAG CTG CCC CCT ACC CCA CCC	1350
	Leu Arg Pro Trp Thr Leu Cys Pro Glu Leu Pro Pro Thr Pro Pro	
	440 445 450	
40	CAC CTA AAG TAC CTG TAC CTT GTG GTA TCT GAC TCT GGC ATC TCA	1395
	His Leu Lys Tyr Leu Tyr Leu Val Val Ser Asp Ser Gly Ile Ser	
	455 460 465	
45	ACT GAC TAC AGC TCA GGG GAC TCC CAG GGA GCC CAA GGG GGC TTA	1440
	Thr Asp Tyr Ser Ser Gly Asp Ser Gln Gly Ala Gln Gly Gly Leu	
	470 475 480	
50	TCC GAT GGC CCC TAC TCC AAC CCT TAT GAG AAC AGC CTT ATC CCA	1485
	Ser Asp Gly Pro Tyr Ser Asn Pro Tyr Glu Asn Ser Leu Ile Pro	
	485 490 495	
55	GCC GCT GAG CCT CTG CCC CCC AGC TAT GTG GCT TGC TCT TAG	1527
	Ala Ala Glu Pro Leu Pro Pro Ser Tyr Val Ala Cys Ser	
	500 505	

I CLAIM:


- 1 1. An expression vector comprising:
 - 2 (a) a first nucleotide sequence capable of expressing a
 - 3 polypeptide having a thrombin proteolytic cleavage site at the
 - 4 carboxyl terminus of said polypeptide, and;
 - 5 (b) a second nucleotide sequence consisting essentially of
 - 6 nucleotides 73 to 750 of a full length human erythropoietin
 - 7 receptor cDNA coding sequence, said second sequence being
 - 8 positioned 3' to said thrombin proteolytic cleavage site and being
 - 9 translationally coupled to said first sequence.
- 1 2. A purified fusion protein consisting essentially of:
 - 2 (a) a first polypeptide segment having an amino terminus
 - 3 and a carboxyl terminus, said segment having a thrombin
 - 4 proteolytic cleavage site at said carboxyl terminus; and
 - 5 (b) a second polypeptide segment consisting essentially of
 - 6 about amino acid 25 to about amino acid 250 of a full length
 - 7 human erythropoietin receptor protein, said second polypeptide
 - 8 segment being covalently coupled to said carboxyl terminus of
 - 9 said first polypeptide segment.
- 1 3. A purified human erythropoietin receptor polypeptide consisting
2 essentially of about amino acid 25 to about amino acid 250 of the full length
3 human erythropoietin receptor protein, said human erythropoietin receptor
4 polypeptide being capable of binding human erythropoietin.
- 1 4. A purified antibody having specific binding affinity for a purified
2 human erythropoietin receptor polypeptide, said polypeptide consisting
3 essentially of about amino acid 25 to about amino acid 250 of the full length
4 human erythropoietin receptor protein, said polypeptide being capable of
5 binding human erythropoietin.

1 5. An immunoassay composition comprising:
2 (a) a solid phase immunoassay reagent; and
3 (b) the protein of claim 3 operably coupled to said reagent.



1 6. An immunoassay composition comprising:
2 (a) a solid phase reagent; and
3 (b) an antibody of claim 4 operably coupled to said reagent.

1 7. A method for obtaining a substantially pure human
2 erythropoietin receptor polypeptide consisting essentially of about amino acid
3 25 to about amino acid 250 of the full length human erythropoietin receptor
4 protein, said human erythropoietin receptor polypeptide being capable of
5 binding erythropoietin, comprising:
6 (a) providing the purified fusion protein of claim 2;
7 (b) treating said fusion protein with thrombin under
8 conditions allowing cleavage of said polypeptide from said fusion
9 protein, to form a digest mixture;
10 (c) adding said digest mixture to a solid phase reagent
11 having erythropoietin coupled thereto, under conditions
12 allowing binding of said polypeptide with said solid phase
13 reagent, to form a polypeptide-solid phase composition;
14 (d) washing said polypeptide-solid phase composition to
15 remove unbound material; and
16 (e) eluting said polypeptide from said polypeptide-solid
17 phase composition.


1/6

**Fig.1**


2/6

Fig. 2A*Fig. 2B*


3/6

Fig. 3


4/6

Fig. 4

5/6

Fig. 5

6/6

Fig. 6

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US94/09298

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C12N 15/62, 15/63; C07K 14/00; G01N 33/543

US CL :435/69.1, 69.7; 530/350, 395; 436/518

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/69.1, 69.7; 530/350, 395; 436/518

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

USPTO-APS; Medline; Biosis, Derwent-WPI

Search terms: thrombin, cleav7, site; erythropoietin receptor; fusion; recombinant?, cDNA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Journal of Biological Chemistry, Volume 267, Number 21, issued 25 July 1992, K. W. Harris et al., "Ligand Binding Properties of the Human Erythropoietin Receptor Extracellular Domain Expressed in <i>Escherichia coli</i> ", pages 15205-15209, especially the abstract and pages 15205, 15206, and 15208.	3
Y		1, 2, 5, 7
Y		1-3, 5, 7
	Blood, Volume 76, Number 1, issued 1990, S. S. Jones et al., "Human Erythropoietin Receptor: Cloning, Expression, and Biologic Characterization", pages 31-35, especially Figs. 1A and 1B.	

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A document defining the general state of the art which is not considered to be of particular relevance	*X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E earlier document published on or after the international filing date	*Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z	document member of the same patent family
*O document referring to an oral disclosure, use, exhibition or other means		
*P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

07 NOVEMBER 1994

Date of mailing of the international search report

07 DEC 1994

 Name and mailing address of the ISA/US
 Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

DAVID L. FITZGERALD

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/09298

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Gene, Volume 67, issued 1988, D. B. Smith et al., "Single-step purification of polypeptides expressed in <i>Escherichia coli</i> as fusions with glutathione S-transferase", pages 31-40, especially the abstract.	1-3, 5, 7
Y	Journal of Cellular Biochemistry, Supplement O, Volume 15, Part F, issued 1991, L. S. Mulcahy et al., "Generation and characterization of a soluble erythropoietin-binding protein" (meeting abstract), page 146, see the entire abstract.	1-3, 5, 7

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/09298

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
1, 2, 3, 5, 7
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/09298

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

- I. Claims 1, 2, and 7, directed to a fusion protein, a corresponding vector, and its use to make protein.
- II. Claims 3 and 5, directed to a soluble EPO receptor protein and an immunoassay composition comprising it.
- III. Claims 4 and 6, directed to an EPO receptor antibody and an immunoassay composition comprising it.

The claims are not so linked by a special technical feature within the meaning of PCT Rule 13.2 so as to form a single inventive concept. The special technical feature of group I which defines an advance over the prior art is a thrombin-cleavable fusion protein which affords advantageous production of a soluble receptor fragment. The special technical feature of group II is a soluble EPO receptor fragment. It does not share the special technical feature of group I because it can be made by alternative methods; for example, enzymatic cleavage of intact receptor or expression of a cDNA encoding only the desired soluble receptor fragment. The special technical feature of group III is an EPO receptor-specific antibody. It does not share the special technical feature of either of groups I or II because it may be alternatively made by immunization against a distinct antigen, for example, purified intact receptor protein or a whole cell expressing the EPO receptor.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☒ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☒ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.